Boston Scientific has received positive guidance from the National Institute for Health and Care Excellence (NICE) in support of the use of its GreenLight XPS Laser Therapy System to treat an enlarged prostate. The agency estimated that use of the system could save the U.K.'s National Health Service (NHS) up to £3.2 million annually by enabling an outpatient procedure for benign prostatic hyperplasia (BPH) rather than the traditional surgical resection.
Coming off a successful first quarter in which four of its 7 businesses posted double-digit organic growth, Boston Scientific is now planning a makeover. The Marlborough, MA-based devicemaker announced a global restructuring program on Wednesday to "support long-term growth and innovation."
Otsuka has given renal denervation to treat hypertension another vote of confidence. It's signed a distribution deal for certain Asian companies with startup ReCor Medical, as well as making an additional investment in the company.
Wall Street heartily embraced Boston Scientific on its first-quarter earnings, driving shares up about 10% in early trading to give the medical device giant a market cap of nearly $30 billion.
Boston Scientific and Edwards Lifesciences have been scuffling over patents for heart valve replacement devices in Europe. Now, the legal battle is expanding to the U.S. as Boston Scientific vies for more market share.
The medical device industry has been working on miniaturizing pacemakers so they can be minimally invasively inserted and cause fewer difficulties for patients. Up next likely are closed-loop systems: pacemakers that record patient data, transmit that data externally and enable adjustment based on that data by physicians or even, eventually, on their own as guided by advanced algorithms.
UPDATED: Boston Scientific faces grand jury probe over allegedly counterfeit material for vaginal mesh
Boston Scientific is facing more pushback in its legal saga over vaginal mesh implants. Federal prosecutors are convening a grand jury to consider evidence that the company used defective counterfeit raw materials from China for its devices.
Boston Scientific is recalling all models of its Fetch 2 Aspiration Catheter. The recall of the thrombectomy catheter is due to shaft breakage complaints--and has been classified as Class 1 by the FDA, indicating that use of the device could result in serious adverse health consequences or death.
Boston Sci suspends EU sales of next-gen Watchman, but CMO says current-gen device is safe and effective
Boston Scientific has suspended European sales of the CE-marked, Watchman FLX to prevent stroke due to a high embolization rate.
As if the hundreds of millions of dollars in paid out in damages to injured patients aren't enough, Boston Scientific'sntroubled vaginal mesh devices have been hit by allegations that they contain a counterfeit material.